APO-Bortezomib bortezomib 3.5mg powder for injection vial

Maa: Australia

Kieli: englanti

Lähde: Department of Health (Therapeutic Goods Administration)

Aktiivinen ainesosa:

bortezomib, Quantity: 3.5 mg

Saatavilla:

Arrotex Pharmaceuticals Pty Ltd

INN (Kansainvälinen yleisnimi):

Bortezomib

Lääkemuoto:

Injection, powder for

Koostumus:

Excipient Ingredients: mannitol

Antoreitti:

Subcutaneous, Intravenous

Kpl paketissa:

1

Prescription tyyppi:

(S4) Prescription Only Medicine

Käyttöaiheet:

Bortezomib, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy.,Bortezomib, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma.,Bortezomib is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy and who have progressive disease.

Tuoteyhteenveto:

Visual Identification: White to off-white powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius

Valtuutuksen tilan:

Licence status A

Valtuutus päivämäärä:

2015-07-22